Stock Market Reviews

MYNZ (Mainz Biomed N.V.) News

Get the latest news, insights, and market updates on MYNZ (Mainz Biomed N.V.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
  Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic TransactionBERKELEY, Calif. and MAINZ, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position, transition the business to a focus on its pancreatic cancer detection program in the U.S., a
  Feb 17, 2026 - $MYNZ
• Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
  First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San DiegoBERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This
  Jan 14, 2026 - $MYNZ
• Mainz Biomed Provides Review of 2025 Highlights
  Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectStudy Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ge
  Jan 5, 2026 - $MYNZ
• 2 Small-Cap Biotechs That Could Reward Patient Investors
  Two small-cap biotech stocks offer high risk but significant upside for patient investors as they advance early-stage diagnostic and antiviral programs
  Dec 12, 2025 - $MYNZ
• DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
  DNA-based Colorectal Cancer Screening as a Home TestBERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in Mainz Biomed’s European growth strategy and
  Dec 2, 2025 - $MYNZ
• Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
  OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and EcuadorBERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the signing of a Memorandum of Understanding (“MOU”) with OncoVanguard8, a distributor of oncological innovations. Th
  Nov 18, 2025 - $MYNZ
• Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
  BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany. With over 5,000 exhibitors from 70 countries and 80,000 visitors expected, MEDICA continues to serve as
  Nov 12, 2025 - $MYNZ
• Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
  BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, 2025, in Bad Kreuznach, Germany. The annual GARPS conference brings together clinical and scientific
  Nov 10, 2025 - $MYNZ
• Mainz Biomed to Attend 2025 Maxim Growth Summit
  BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23, 2025, at The Hard Rock Hotel NYC. The prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancement
  Oct 15, 2025 - $MYNZ
• Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
  Study Demonstrated a Sensitivity of 100% and Specificity of 95%Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year. The study confirmed the strong clinical accuracy and utility of licensed proprietary biomarke
  Oct 8, 2025 - $MYNZ